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Background: One of the most frequently found abnormalities in acute myeloid leukemia (AML) is the t(8;21)(q22;
q22) translocation, which is seen in around 15% of patients. This translocation results in the production of the
AML1/ETO (A/E) fusion protein and commonly involves cooperating activating mutations of RAS. AE9a encodes
a C-terminally truncated A/E protein of 575 amino acids that retains the ability to recruit histone deacetylases
(HDACs). Expression of AE9a leads to rapid development of leukemia in experimental mouse systems. We have
recently shown that treatment of mice bearing A/E9a;NrasG12D tumors with the histone deacetylase inhibitor
(HDACi) panobinostat leads to degradation of the A/E9a fusion protein, cell cycle arrest, differentiation of AML
blasts into mature granulocytes and prolonged survival. Herein, we sought to enhance this therapeutic effect.
Findings: Combined treatment of mice bearing A/E9a;NrasG12D leukemias with panobinostat and arsenic trioxide
(ATO) resulted in a significant survival advantage compared to mice treated with either agent alone. Moreover,
some of the mice treated with the panobinostat/ATO combination showed complete tumor responses and
remained in remission for over 220 days. Panobinostat caused differentiation of A/E9a;NrasG12D cells while ATO
induced apoptosis of the leukemic cells, an effect that was enhanced following co-treatment with panobinostat.
Conclusions: Our results indicate that leukemic blast differentiation mediated by panobinostat combined with induction
of apoptosis by ATO could be therapeutically beneficial and should be considered for patients with t(8;21) AML.
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One of the most frequently found abnormalities in acute
myeloid leukemia (AML) is the t(8;21)(q22;q22) trans-
location, which is seen in around 15% of patients [1].
The eight twenty-one (ETO) portion of the AML1/ETO
(A/E) fusion protein recruits histone deacetylases
(HDACs) providing a molecular rationale for using
HDAC inhibitors (HDACi) as a therapeutic strategy.
We have generated a transplantable model of mouse* Correspondence: ricky.johnstone@petermac.org
1Cancer Therapeutics Program, Peter MacCallum Cancer Centre, St. Andrews
Place, East Melbourne 3002, VIC, Australia
5The Sir Peter MacCallum Department of Oncology, University of Melbourne,
Parkville 3010, VIC, Australia
Full list of author information is available at the end of the article
© 2015 Salmon et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.AML driven by concomitant expression of the AML1/
ETO9a splice variant of A/E (AE9a) and NrasG12D that
recapitulates the genetics and pathology of human t(8;21)
AML [2]. Treatment of mice bearing A/E9a;NrasG12D tu-
mors with the HDACi panobinostat leads to degradation
of the A/E9a fusion protein, cell cycle arrest, differenti-
ation of AML blasts into mature granulocytes, and pro-
longed survival [3].A combination of panobinostat and arsenic trioxide
significantly increases the survival of mice transplanted
with A/E9a;NrasG12D tumors
Given our recent studies demonstrating that treatment of
mice bearing A/E9a;NrasG12D tumors with panobinostatl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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amined the effect of combining panobinostat with
ATO in this model. The C57Bl/6 mice transplanted
with A/E9a;NrasG12D leukemia cells were treated with
either vehicle, panobinostat alone, ATO alone, or the
combination of panobinostat and ATO (Figure 1A).
The treatment schedule involved an initial week of
a high dose of panobinostat (darker shaded area)
followed by three weeks of a lower dose of panobino-
stat combined with ATO (lighter shaded area). As pre-
viously reported [3], we observed a clear survival
benefit following treatment with panobinostat alone
(median survival 66 days). Strikingly, treatment with a
combination of panobinostat and ATO extended this
survival window (median survival was 105 days) with
some individual mice showing no detectable tumor
cells in the peripheral blood several months after ces-
sation of therapy (not shown). Treatment with ATO
alone resulted in no significant survival advantage
compared to vehicle-treated mice (7 days versus 9
days, respectively). To examine the acute effect of the
ATO and panobinostat combination, we analyzed
tumor burden following 5 days of therapy. The per-
centage of GFP-positive cells in the peripheral blood
was reduced following single-agent treatment with
panobinostat or ATO alone (Figure 1B) with a more
substantial reduction in tumor burden demonstrated
following combination treatment with panobinostat
and ATO (Figure 1B). These results demonstrate that
while ATO alone has a marginal effect on A/E9a;
NrasG12D tumor cells, it has no effect on overall sur-
vival. However, when combined with panobinostat,
ATO confers a significant survival advantage, superior
to that of panobinostat alone.Figure 1 A combination of the HDACi panobinostat and arsenic triox
A/E9a;Nras-driven tumors. (A) Kaplan-Meier survival curves of mice bearin
(downward triangle), panobinostat (square), ATO (upward triangle) or a com
Median survival benefit of panobinostat + ATO combination over panobino
**P <0.001). Dotted lines indicate treatment days (5 days/ week; Monday th
a high dose of panobinostat (25 mg/kg) and the lighter shaded areas indic
(15 mg/kg). (B) Flow cytometry analysis of GFP-positive cells in the periphe
treatment group. Data are represented as the mean plus the standard erroArsenic trioxide causes leukemia cell death
We next sought to investigate how the panobinostat and
ATO combination leads to increased survival benefit.
Because panobinostat leads to terminal differentiation of
A/E9a;NrasG12D cells [3], we began by examining the
effect on tumor cell differentiation caused by panobino-
stat with or without the addition of ATO. Mice bearing
A/E9a;NrasG12D tumors were treated with panobinostat
with and without ATO, and the differentiation of tumor
cells was examined at weekly intervals using flow cytom-
etry to detect cell surface expression of myeloid markers
c-Kit, Sca1, Mac1 and Gr1. A reduction of c-Kit and
increased expression of Sca1, Mac1 and Gr1, indicative
of terminal myeloid differentiation, was observed on
A/E9a;NrasG12D cells harvested from panobinostat-
treated mice. Even after 3 weeks of therapy, the differen-
tiation of tumor cells mediated by panobinostat was not
enhanced following combination treatment (Figure 2A).
These data indicate that ATO does not augment the dif-
ferentiating effect of panobinostat despite further redu-
cing tumor burden and enhancing survival of tumor-
bearing mice.
We then analyzed the induction of tumor cell apop-
tosis following ATO treatment of mice transplanted with
A/E9a;NrasG12D cells. As we have previously demon-
strated [3], panobinostat did not induce substantial
tumor cell apoptosis 4 hrs after treatment, whereas com-
bined treatment with panobinostat and ATO resulted in
an increase in apoptotic A/E9a;NrasG12D cells (Figure 2B
and C). The apoptotic effect of the combination of pano-
binostat and ATO was more striking in vivo as assessed
by TUNEL assay. Bone marrow sections from tumor-
bearing mice treated with the panobinostat and ATO
combination demonstrated high TUNEL-positivity afteride (ATO) demonstrates greater therapeutic efficacy against
g A/E9a;NrasG12D-driven leukemias treated with either vehicle
bination of panobinostat (pan) and ATO (circle). (n = 6 mice/group.
stat alone is 38.5 days; *P <0.05. and 95.5 days over vehicle alone;
rough Fri) with the darker shaded area indicating the first week with
ating the following three weeks with a lower dose of panobinostat
ral blood of mice treated for 5 days as indicated. (n = 3 to 6 mice per
r of the mean (SEM). *P <0.02).
Figure 2 (See legend on next page.)
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Figure 2 The combined effects of panobinostat and arsenic trioxide (ATO) include the differentiation of A/E9a;NrasG12D-leukemic blasts
by panobinostat and induction of apoptosis by ATO. (A) Flow cytometry analysis of the cell surface expression of c-Kit; Sca1; Mac1 and
Gr1 of GFP-positive tumor cells in the bone marrow of A/E9a;NrasG12D tumor- bearing mice treated for 5 days with either panobinostat (pan; 25 mg/kg)
or panobinostat combined with ATO (2.5 mg/kg). (n = 3; data are expressed as mean plus SEM; *P <0.05, **P <0.001) (B) Representative dot plots of
AnnexinV-PI staining of tumor cells isolated from the bone marrow of A/E9a; NrasG12D tumor-bearing mice treated for 4 hours with either panobinostat
(25 mg/kg) or ATO (2.5 mg/kg) or a combination. Numbers given are the percentage of total cell population. (C) Normalized expression of AnnexinV
on tumor cells treated with vehicle, panobinostat, ATO or a combination (n = 3; data are expressed as mean plus SEM). (D) Quantification of terminal
deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) positivity as a proportion of total cell area (n = 3; *P <0.001) (E) Representative
images of hematoxylin-eosin staining (H&E; upper panels) and analysis of apoptotic cells by TUNEL staining, and counterstained with hematoxylin
(lower panels). Staining was performed on de-calcified femurs isolated from A/E9a;NrasG12D tumor-bearing mice treated for 4 hours as indicated.
Imaging was performed using 60x objective (scale bars = 50 μm).
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(Figure 2D and E). Thus, the enhanced therapeutic effect
of panobinostat and ATO is likely due to the combined
effects of differentiation induced by panobinostat and
apoptosis induced by ATO.
Degradation of promyelocytic leukemia protein occurs
in response to arsenic trioxide in acute myeloid
leukemia tumors
Panobinostat causes degradation of A/E and A/E9a that
precedes induction of tumor cell differentiation [3], and
we sought to determine the effect of the panobinostat
and ATO combination on expression of A/E9a (Figure 3A).
Treatment with panobinostat but without ATO resulted
in the degradation of A/E9a, and this depletion of the
oncogenic fusion protein was not enhanced following
addition of ATO (Figure 3A). Immunoblot for acetylated
Histone H3 was also performed to confirm the HDAC in-
hibitory activity of panobinostat, and we observed no
change in histone acetylation following ATO treatment
(Figure 3A).
To further detect changes associated with ATO that
correlate with therapeutic efficacy in mice bearing A/E9a;Figure 3 Arsenic trioxide (ATO) does not enhance degradation of t
panobinostat but does lead to degradation of promyelocytic leuke
Immunoblotting of whole cell lysates prepared from A/E9a;NrasG12D tum
ATO (2.5 μM) or a combination, for 24 hours using antibodies against A
loading control. (B) Immunoblotting of whole cell lysates prepared from A/E9
ATO (2.5 μM) or the combination, for 24 hours using antibodies against
are representative of three experiments.NrasG12D tumors, we investigated the levels of PML pro-
tein levels by immunoblot. ATO binding induces PML
oligomerization, which increases its interaction with the
small ubiquitin-like modifier (SUMO)-conjugating en-
zyme 9, resulting in enhanced SUMOylation and degrad-
ation of PML [4]. No change in PML expression was
observed in A/E9a;Nras tumor cells treated in vitro for
24 hours with either vehicle (DMSO) or panobinostat
(Figure 3B). In contrast, treatment with ATO in the pres-
ence or absence of panobinostat resulted in a substantial
decrease in PML expression (Figure 3B).
Discussion
The successful introduction of ATO in combination with
retinoids for the treatment of t(15;17) acute promyelocy-
tic leukemia (APL) has resulted in cure rates of up to
90% in both newly diagnosed and relapsed APL patients
with few side effects [5,6]. The mechanisms of ATO-
mediated tumor cell responses include inactivation of
key proliferation and survival pathways including the
hedgehog, MAP kinase, NfκB and PI3K/AKT signaling
pathways [5]. In addition, increased oxidative stress,
downregulation of Bcl2, and degradation of PML nuclearhe Ae9a fusion protein or the cell cycle arrest induced by
mia (PML) protein in A/E9a;NrasG12D tumor cells. (A)
or cells treated in vitro with either panobinostat (pan; 16 μM),
/E9a or acetylated histone H3 (AcH3), with β-actin serving as a
a;NrasG12D tumor cells treated in vitro with either panobinostat (16 μM),
PML with β-actin serving as a loading control. The results shown
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mechanisms of action of ATO suggest that it may have
pro-apoptotic activity in hematological malignancies
other than APL and chronic myeloid leukemia (CML)
and that its use in combination with other targeted ther-
apies may also be beneficial. In the present study, we ex-
amined the effect of the combination of ATO with the
HDAC-inhibitor panobinostat using a pre-clinical mouse
model of t(8;21) AML. Our results indicate that the
additive effects of leukemic blast differentiation medi-
ated by panobinostat with induction of apoptosis by
ATO could be therapeutically beneficial.
Although HDAC-inhibitors have been minimally suc-
cessful in the clinic when used as single agents, it is
likely that they will be best utilized when combined with
other anti-cancer agents. At the onset of this investiga-
tion, we performed toxicity studies on mice not bearing
tumors to determine the maximum tolerated dose
(MTD) of ATO as a single agent or in a combination.
Upon establishing our dosing schedule, we observed an
initial but not significant weight loss and no significant
additional hematological toxicity (see Additional file 1:
Figure S1A). Importantly, thrombocytopenia, which is
the major dose-limiting toxicity associated with HDACi,
in mice receiving the combination of panobinostat and
ATO, was similar during the course of therapy to that of
mice receiving panobinostat alone (see Additional file 1:
Figure S1B).
Contrary to our observations, the combination of
HDAC-inhibitors and ATO had previously been re-
ported to be antagonistic in some leukemic cell lines
[10]. Using our pre-clinical model of t(8;21) AML we
demonstrated striking combined therapeutic efficacy
using panobinostat and ATO. Panobinostat induces
rapid degradation of A/E9a and A/E that precedes tumor
cell differentiation [3]. Treatment with ATO alone had
no effect on the expression of A/E9a and did not alter
the panobinostat response when used in combination.
While much of the focus has centered on the degrad-
ation of PML and PML-RARα in APL in response to
arsenic [11], there are numerous studies reporting the
pro-apoptotic actions of ATO via PML degradation in
non-APL cells [12]. Cells ectopically expressing A/E
have been demonstrated to have increased PML bodies
[13] and altered nuclear structure [14] and thus may be
sensitized to PML degradation. It remains unclear why
ATO as a single agent had no effect on the survival of
mice bearing A/E9a;NrasG12D leukemias as we did ob-
serve degradation of PML and apoptosis with the use of
ATO as a single agent. In addition, we observed that the
combination of panobinostat and ATO actually resulted
in a decrease in PML degradation. PML is known to
interact with HDACs [15,16], in particular, HDAC7 is re-
quired for the SUMOylation of PML which enhances itsdegradation [17]. It is possible that inhibition of HDAC
activity leads to the partial rescue of PML degradation
caused by ATO. Regardless, we demonstrate that com-
bining panobinostat with the apoptosis-inducing agent
ATO in mice bearing A/E9a/NrasG12D tumors resulted
in a significant survival advantage compared to tumor-
bearing mice treated with single agents alone.
We propose that patients with t(8;21) AML may
benefit from this type of targeted combination ther-
apy. Indeed, a similar strategy has been extraordinarily
successful in improving the treatment for acute pro-
myelocytic leukemia resulting from the t(15;17) trans-
location. In that subtype of AML, treatment with
all-trans-retinoic acid (ATRA) and ATO results in
degradation of the PML-RARα fusion oncogene, differ-
entiation of tumor cells, and apoptosis in leukemic blasts.
The similarities between our results using panobinostat in
combination with ATO in mice bearing A/E9a;NrasG12D
tumors and the effects of retinoids and ATO in models of
PML-RARα-driven APL indicate that, as differentiation
therapy combined with ATO has been so successful in
curing patients with PML, the combination of panobino-




All reported research involving the use of animals was
approved by the Animal Experimentation Ethics Com-
mittee (AEEC) at the Peter MacCallum Cancer Centre
(ref. E472). C57BL/6 mice were purchased from the
Walter and Eliza Hall Institute of Medical Research.
Panobinostat was provided by Novartis and prepared as
a 2 mg/mL solution in 5% dextrose/dH2O (D5W). Ar-
senic trioxide (Phenasen™) was obtained from the Peter
MacCallum Cancer Centre and further diluted in
phosphate-buffered saline to a 0.5 mg/mL solution.
Mouse transplants
Mouse tumors expressing MSCV-AML1/ETO9a-IRES-
GFP (A/E9a) and MSCV-luciferase-IRES-NrasG12D (A/
E9a;NrasG12D) were generated as previously described [3].
At the terminal disease stage, mice were euthanized
and leukemia cells were isolated from the bone marrow
and spleen. Single-cell suspensions were prepared, and
cells were cryopreserved in fetal calf serum (FCS)/10%
dimethylsulfoxide (DMSO). Total white blood cell (WBC)
counts were obtained using the CELL-DYN Sapphire
Hematology System (Abbott Laboratories, Lane Cove,
NSW, Australia).
To perform therapeutic studies, A/E9a;NrasG12D
leukemia cells (1 × 106) were then serially transplanted
into sublethally irradiated mice by intravenous injection.
Treatment was initiated once the leukemic burden reached
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Mice were treated daily for 5 consecutive days per week via
intraperitoneal injection over 4 weeks. Treatment cohorts
were either (1) ATO (2.5 mg/kg); (2) panobinostat (25 mg/
kg) for 1 week followed by 15 mg/kg for 3 weeks; (3) pano-
binostat (25 mg/kg) for 1 week followed by panobinostat
(15 mg/kg) combined with ATO (2.5 mg/kg); or (4) control
mice receiving an equivalent volume of vehicle.
Cell culture conditions
A/E9a;NrasG12D leukemia cells were cultured ex vivo at
37°C under 5% CO2 in RPMI-1640 (Gibco, Grand Island,
NY, USA) containing 20% FCS supplemented with 10
ng/mL IL-3, 10 ng/mL IL-6 and 50 ng/mL SCF (all
Peprotech, Rocky Hill, NJ, USA). Cells were treated with
panobinostat (16 nM) and/or ATO (2.5 μM) for 24
hours or the equivalent volume of vehicle.
Western blot analysis
Whole cell lysates were separated by sodium dodecyl sul-
fate polyacrylamide gel electrophoresis and transferred
onto polyvinylidene difluoride membranes (Millipore,
Darmstadt, Germany). Membranes were blocked with 5%
nonfat milk in Tris-buffered saline/0.1% Tween-20 at room
temperature and incubated overnight with antibodies
against AML1 (4336; Cell Signaling Technology, Danvers,
MA, USA), acetyl-histone H3 (06–599; Millipore),
PML (05–718; Millipore), or β-actin (A2228; Sigma-
Aldrich, St Louis, MO, USA) at 4°C. Membranes were
developed using appropriate horseradish peroxidase–
coupled secondary antibodies (Dako, Glostrup, Denmark)
and enhanced chemiluminescence (GE Healthcare, Little
Chalfont, UK).
Differentiation markers
Cell suspensions were incubated in red cell lysis buffer
(150 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) and
washed twice in fluorescence-activated cell sorter (FACS)
staining buffer (phosphate-buffered saline supplemented
with 2% FCS and 0.02% NaN3). Cells were pre-incubated
with blocking anti-CD16/CD32 (2.4G2) and stained on ice
with antibodies specific for c-Kit (CD117), Sca1 (Ly6A/E),
Mac-1 (CD11b) and Gr1 (Ly6G; all BD Biosciences, San
Jose, USA) in FACS staining buffer for 30 minutes. Data
were collected on a FACSCanto II flow cytometer (BD




nick end labeling (TUNEL) staining was performed
using the Apoptag Peroxidase In Situ Apoptosis Detec-
tion Kit (Millipore). Sections were counterstained using
hematoxylin, and images were recorded with a Zeissmicroscope and a × 60 lens. Quantitation of positive
TUNEL staining was performed using MetaMorph™
Microscopy Automation & Image Analysis Software
(http://www.moleculardevices.com/metamorph).
Cells were isolated from the femurs of treated mice and
stained with APC-conjugated AnnexinV (BD Biosciences)
and 1 μg/ml propidium iodide in AnnexinV binding buffer
(10 mM HEPES/NaOH [pH 7.4], 140 mM NaCl, 5 mM
CaCl2x2H2O) to detect dead or dying cells by flow cytom-
etry. Data were collected on a FACSCanto II flow
cytometer (BD Biosciences) and analyzed using FlowJo
software (Tree Star).
Statistical analysis
Kaplan-Meier survival curves were created, and survival
of mice (using a log-rank test) was statistically analyzed
with GraphPad Prism software (http://www.graphpad.
com/scientific-software/prism/). All other statistical ana-
lyses (using a 2-tailed unpaired Student t test) were also
performed with this software.
Additional file
Additional file 1: Figure S1. Combination therapy of panobinostat and
arsenic trioxide (ATO) has no significant toxicity over single agents alone.
(A) Mice were treated with either ATO alone or with a combination of
ATO and panobinostat. Weight of treated mice was monitored daily
throughout the course of therapy. Data are mean plus SEM. n = 6 mice
per treatment group. (B) Platelet counts from mice treated with either
vehicle, panobinostat, or a combination of panobinostat and ATO.
Peripheral blood was taken to monitor thrombocytopenia throughout the
therapy at weekly intervals. Data are mean plus SEM, n = 3 mice per
treatment group.
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